Compare FEAM & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEAM | DXR |
|---|---|---|
| Founded | 2016 | 1970 |
| Country | United States | United States |
| Employees | 35 | N/A |
| Industry | Major Chemicals | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 81.4M | 71.4M |
| IPO Year | N/A | 1995 |
| Metric | FEAM | DXR |
|---|---|---|
| Price | $1.82 | $11.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $6.38 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 344.2K | 12.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $1,446,345.00 |
| Revenue This Year | N/A | $44,935.22 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $33.83 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.66 | $7.10 |
| 52 Week High | $7.50 | $14.76 |
| Indicator | FEAM | DXR |
|---|---|---|
| Relative Strength Index (RSI) | 38.30 | 36.19 |
| Support Level | $1.66 | $10.00 |
| Resistance Level | $2.16 | $11.32 |
| Average True Range (ATR) | 0.18 | 0.37 |
| MACD | 0.03 | -0.04 |
| Stochastic Oscillator | 31.00 | 14.71 |
5E Advanced Materials Inc is an exploration stage company focused on becoming a vertically integrated supplier of specialty boron and boron derivative materials whose mission is to enable decarbonization, increase food security, and ensure domestic supply of critical materials. It has a project located in southern California underpinned by a mineral resource that includes boron and lithium, with the boron being contained in a conventional boron mineral known as colemanite. The company seeks to extract and process the minerals into boric acid, boron materials, lithium carbonate, and potentially other co-products on a commercial scale.
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.